OPTIMAL TREATMENT OF RETINAL DISEASE LEVERAGING NOVEL DELIVERY TECHNOLOGY
Everads: more effective, durable treatment for retinal diseases.
Our technology facilitates targeted, rapid delivery of therapy via the emerging suprachoroidal delivery route. Leveraging our technology, we are developing treatments to improve efficacy and reduce treatment burden, and also partnering with leading pharmaceutical and biotech companies to enable delivery of novel therapies using our technology.
About Everads
Everads is an emerging startup with novel delivery technology to treat retinal diseases via suprachoroidal administration and is developing an early-stage pipeline that leverages our technology. Our technology enables delivery of therapy to the choroid and retina via the suprachoroidal space (SCS)….
Everads News
December 2024
Overview of Clinical Data using Everads Technology Featured at Floretina2024
Clinical experience using Everads’ suprachoroidal delivery injector was presented at the Floretina2024 meeting held December 5-8. In a symposium moderated by Dr. Quan Nguyen and titled Further Progress on Suprachoroidal Delivery for Ocular Diseases, Dr. Yoreh Barak, Head of Retina at Rambam Medical Center and PI in Everads’ clinical trial, presented an overview of Everads’ technology and results from the ongoing clinical trial.
September 2024
Everads Leads Suprachoroidal Workshop at Gene Therapy for Ophthalmic Disorders Summit
Everads therapy CEO, Moshe Weinstein, and Head of Scientific Strategy, Dr. Keren Mano Tamir, co lead the suprachoroidal innovations pre-conference workshop at the 5th Annual Gene Therapy for Ophthalmic Disorders Conference in Boston. The session was co-lead by Rachel Eclov, Sr. Director, Opthalmology, of Kriya Therapeutics. The workshop provided a dead-dive into suprachoroidal delivery for gene therapy, including a review of suprachoroidal delivery and various delivery technologies, preclinical considerations for device and capsid and clinical updates from Everads first in human clinical trial.
November 2024
Everads Suprachoroidal Delivery Featured at OIS XIV Conference
Everads’ suprachoroidal delivery platform was presented at the Ophthalmology Innovation Source (OIS) 14th annual conference held in San Diego on November 22-23rd (ois.net/ois-xiv/). As part of a panel session titled “Spotlight on Suprachoroidal Drug Delivery”, Moshe Weinstein, Everads CEO, shared recent updates from the company’s ongoing clinical trial, as well as provided an overview of Everads’ internal and license-partner pipeline.
September 2024
Everads Presents Clinical Data from First-in-Human Trial of Suprachoroidal Delivery Technology at EURETINA
Presentation : Everads Therapy
September 2024
Everads wins startup competition at the Eye and Beyond II Conference
Everads is excited to announce that it was selected as the top startup at the Eye and Beyond II conference hosted by the Ophthalmology Division of the Rabin Medical Center. The Eye & Beyond ophthalmic conference is a bi annual conference for innovation in ophthalmology. The presentation, delivered by Keren Mano Tamir, MD, Head of Scientific Strategy at Everads was recognized as the most promising ophthalmic startup for 2024.
May 2024
2 Posters at ARVO show AAV-GFP Transduction to Macular RPE and Past Posterior Pole in NHP Achieved with Everads Delivery Technology
Everads is excited to announce the presentation of two posters at ARVO 2024 featuring results in non-human primates using Everads suprachoroidal delivery technology. Eclov et al reported achieving circumferential transduction past the posterior pole using AAV2 after suprachoroidal injection in NHPs and Barak et al demonstrated the delivery of AAV5-GFP to the Macular RPE.
Access the abstracts/posters here: Eclov et al and Barak et al
